XOMA shares soar on IL-1 antibody deal with Servier
This article was originally published in Scrip
Executive Summary
US biotech XOMA inked a deal potentially worth more than $500 million to develop and commercialise its experimental interleukin-1 beta antibody XOMA 052 with French pharma Les Laboratoires Servier.